Telemedical management of symptomatic COVID-19 outpatients.
Aenne Solvejg von FalkenhausenScott GeipelAntonia GailClemens SchererSven StockhausenLauren E SamsFinn BeckerPhilipp M DoldiEric LemmermöhlePaul de VillèleMichael SchleefMarc BeckerMoritz LauterbachSteffen MassbergStefan KääbMoritz F SinnerPublished in: ERJ open research (2024)
COVID-SMART is the first randomised clinical trial assessing the benefit of telemedicine in an acute respiratory infectious disease. Whereas telemedical management did not reduce the primary end-point of hospitalisation, fewer intervention group patients used outpatient-based emergency services, suggesting a potential benefit for less-acutely infected individuals.
Keyphrases
- clinical trial
- coronavirus disease
- sars cov
- end stage renal disease
- infectious diseases
- randomized controlled trial
- healthcare
- ejection fraction
- open label
- newly diagnosed
- chronic kidney disease
- emergency department
- study protocol
- public health
- double blind
- liver failure
- prognostic factors
- peritoneal dialysis
- primary care
- respiratory syndrome coronavirus
- risk assessment
- hepatitis b virus
- patient reported outcomes
- intensive care unit
- drug induced
- phase iii
- placebo controlled
- respiratory tract